Γενόσημα και βιοοικονομία
KeywordsΓενόσημα φάρμακα ; Βιο-ομοειδή φάρμακα ; Φαρμακοβιομηχανία ; Φαρμακευτική δαπάνη ; Βιώσιμο σύστημα
Generic are called the pharmaceutical products the replace the prototype after the patent expire. They don’t need specific trials before launching in the market. Also there is very low cost on Research and Development. In many cases manufacturers of the prototype medicine, produce generics too. It doesn’t need to be licensed for entering in the market. WHO promotes generics as the solution for the sustainability of Health System because the reduce the medical cost. The aim is the expansion of generic market share. Every country applies its own policy for generic marketing and pricing, in order to increase generic sales and reduce medical cost. The demand raise created opportunities for pharmaceutical industries to enter in new markets. Among them many Greek industries created alliances and collaborations and expanded in new markets. Although the generic share in Greek market is 32%, there are many popular Greek generic products. Due to competitive prices of prototype medicines and the skepticism of Greek patients the generics are not accepted yet. Within next few years is expected the generic market share to increase to 65%. In order to achieve this goal, the Greek government created generic marketing strategies, as well as pricing policies for more competitive generics.